A Periodical for the Sarcoma Community

November 2013 - Volume 10, Numbers 5-6

A Ten-Year Journey

Editorial by Bruce Shriver, PhD

Thank You

Guest Editorial by Robert Maki, MD PhD

Opinions and Hypotheses

Personalized Medicine for Sarcomas: Have We Lost Perspective?

Dr. David Thomas takes a step back to consider personalized medicine in the context of costs, results and pressing global health issues.

Feature Articles

Evaluation of Genetic Biomarkers in the P53 Pathway for Sarcoma Susceptibility

Experimental Plan: Dr. Bond and his colleagues describe their study of the molecular defects that disrupt the p53 pathway in the onset of sarcomas.

Zoledronic Acid with Chemotherapy for Ewing's Sarcoma

Study Report: Drs. Odri, Corradini and Rédini report on zoledronic acid as a promising therapeutic option for primary bone Ewing's sarcoma tumors and as an inhibitor of lung metastasis dissemination.

The Online Experience of Sarcoma Patients and Their Supporters Print the Sarcoma Survey Report

Survey Report: Mary Sorens writes about the results of the Initiative's global online survey of sarcoma patients and their supporters.

Considering the Patient

Special Feature: Dr. Kate Granger shares a few of the lessons she's learned as a DSRCT patient.


$40,000 Grant Funds Research on Sarcoma Susceptibility

The Liddy Shriver Sarcoma Initiative has awarded an International Collaborative Grant for sarcoma research in Australia, Germany and the United Kingdom.

Translated Articles

Sarcoma Sinoviale

Marilena Cesari, MD provides an Italian translation of the ESUN overview and review article on synovial sarcoma.


Koichi Ogura, MD provides a Japanese translation of the ESUN overview and review article on dermatofibrosarcoma protuberans.